Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 2/20 | 0.32 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780058 | 0.84 | LMNA (0.39) | PRKDCALDH1A1ALOX15PIK3CAL3MBTL1 | |
| SCHEMBL9761613 | 0.84 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1BCAT2 | |
| SCHEMBL5638807 | 0.81 | L3MBTL1 (0.38) | ALDH1A1L3MBTL1BCAT2 | |
| SCHEMBL5548265 | 0.80 | CA1 (0.41) | ALDH1A1 | |
| SCHEMBL27298860 | 0.79 | CCR2 (0.37) | ALDH1A1ALOX15CCR2BCAT2EPAS1 | |
| SCHEMBL9649698 | 0.77 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1CCR2 | |
| SCHEMBL8678853 | 0.77 | SMN1; SMN2 (0.35) | ALDH1A1L3MBTL1 | |
| SCHEMBL27346257 | 0.77 | ALDH1A1 (0.39) | ALDH1A1ALOX15 | |
| SCHEMBL27746541 | 0.76 | HPGD (0.43) | ALDH1A1ALOX15L3MBTL1 | |
| SCHEMBL6364782 | 0.76 | CES2 (0.48) | ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | PRKDC 480/4885ALDH1A1 3391/4885ALOX15 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.